Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies

Eric NormanFoCUS, Research Briefs

This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect … Read More

Implementation Brief: Understanding access issues for new therapies

Eric NormanFoCUS, Research Briefs

Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with … Read More

Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform

Eric NormanFoCUS, Publications, Whitepapers

Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. … Read More

Are Cell and Gene Therapy programs a better bet?

Eric NormanFoCUS, Research Briefs

Compared to traditional drug development programs, do durable cell and gene therapy (CGT) programs experience higher or lower clinical success rates? Estimating the Probability of Technical and Regulatory Success (PTRS) … Read More

How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?

Eric NormanFoCUS, Research Briefs

Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More

Precision for Whom? Partnering with patients to ensure that Precision Medicine targets what matters

Eric NormanLEAPS, Research Briefs

Despite decades of growth and adaptation in patient engagement, knowing or being able to find guidance for whichmodel or approach will be most impactful in which healthcare or research context … Read More

Emerging market solutions for financing and reimbursement of durable cell and gene therapies

Eric NormanFoCUS, Whitepapers

The FoCUS project was launched in 2016 with the aim of developing precision financing solutions that address the challenges and financial impact created by durable cell and gene therapies entering … Read More

The resource navigation challenges for patients and caregivers

Eric NormanFoCUS, Research Briefs

Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More